SEATTLE and CAMBRIDGE, Mass., Jan. 7, 2026 — InduPro, a biotechnology company focused on membrane protein spatial relationships, has signed a global strategic collaboration and licensing agreement with Eli Lilly and Company, accompanied by an equity investment from Lilly. The collaboration covers up to three targets and could be worth up to approximately $950 million.
The companies will use InduPro’s proximity-guided platform to discover Tumor Associated Proximity Antigens (TAPAs), surface proteins that are spatially co-localized with tumor-associated antigens (TAAs) in the tumor microenvironment. By identifying disease-specific protein-target pairs, the approach aims to enable bispecific antibody drug conjugates and multispecific T-cell engagers with improved safety, potency and tumor selectivity.
Under the agreement, Lilly will gain access to InduPro’s AI/ML-enabled membrane interactomics (MInt) platform. InduPro will lead early discovery to identify co-target pairs and advance bispecific and multispecific antibody programs arising from the collaboration.
“Our partnership with Lilly underscores a shared commitment to advancing a new generation of tumor-selective medicines guided by the spatial biology of cancer,” said Prakash Raman, PhD, CEO of InduPro. “TAPAs represent a fundamentally new way to think about tumor antigens, and Lilly shares our vision of leveraging proximity-based biology to enable precision multi-specific therapeutics.”
InduPro’s induced proximity approach therapeutically targets cell surface proteins by mapping protein neighborhoods with high-resolution proximity labeling technology. The company uses this mapping to discover co-target pairs that are selective for specific disease biology and to generate potential first-in-class and best-in-class therapeutic candidates across multiple indications and modalities.
Leave a Reply